PharmaCyte Biotech Inc (PMCB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.77M
Last updated: Nov 17, 2026 at 11:05 AM ET
PharmaCyte Biotech Inc (PMCB) Financials: Revenue, Profit and Cash Flow
PharmaCyte Biotech reported revenue of $0 for the fiscal year ended Apr 30, 2026. That year, net income was -$19.42M and operating cash flow was -$5.15M. The quarter ended Jul 31, 2026 had revenue of $0 and net income of -$5.08M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Apr 2026, with an operating loss of $6.85M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Apr 2026 | $0 | N/A | N/A | N/A | N/A |
| Apr 2025 | $0 | N/A | N/A | N/A | N/A |
| Apr 2024 | $0 | N/A | N/A | N/A | N/A |
| Apr 2023 | $0 | N/A | N/A | N/A | N/A |
| Apr 2022 | $0 | N/A | N/A | N/A | N/A |
| Apr 2021 | $0 | N/A | N/A | N/A | N/A |
| Apr 2020 | $0 | N/A | N/A | N/A | N/A |
| Apr 2019 | $0 | N/A | N/A | N/A | N/A |
| Apr 2018 | $0 | N/A | N/A | N/A | N/A |
| Apr 2017 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Apr 2026, the company posted a net loss after a profit the year before. In the quarter ended Jul 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $1.23M | $1.54M | $1.43M | $1.59M | $1.56M | $2.22M | $1.97M |
| Gross profit | $0 | $0 | $0 | -$1.23M | -$1.54M | -$1.43M | -$1.59M | -$1.56M | -$2.22M | -$1.97M |
| Research and development | $391.30K | $438.42K | $407.43K | $468.54K | $690.94K | $916.25K | $301.22K | $460.05K | $2.00M | $1.18M |
| Operating income | -$6.85M | -$4.38M | -$8.52M | -$6.46M | -$4.39M | -$3.62M | -$3.83M | -$4.10M | -$6.98M | -$4.44M |
| Net income | -$19.42M | $30.66M | $333.76K | -$4.32M | -$4.24M | -$3.55M | -$3.83M | -$4.07M | -$6.83M | -$4.44M |
| EBITDA | N/A | $29.24M | -$3.07M | -$6.25M | N/A | -$3.55M | N/A | -$4.07M | -$6.83M | -$4.44M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | $0 | N/A | $0 | $0 | $0 | $905.68K | $0 | $0 | $0 | $1.09M | -$620.78K | -$229.16K |
| Operating income | -$1.01M | -$2.51M | -$2.12M | -$1.38M | -$848.30K | -$1.04M | -$960.25K | -$1.11M | -$1.27M | -$3.17M | -$1.87M | -$1.41M |
| Net income | -$5.08M | -$4.39M | $746.86K | -$7.42M | -$8.36M | $11.75M | -$3.05M | -$1.47M | $23.42M | $1.35M | -$619.54K | $2.79M |
Balance Sheet
As of Apr 2026, cash and equivalents of $18.60M were 39.8% of total assets of $46.75M, against total liabilities of $11.77M.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $46.75M | $55.17M | $59.90M | $73.28M | $90.62M | $7.40M | $6.17M | $5.78M | $6.41M | $8.67M |
| Current assets | $37.42M | $22.38M | $50.44M | $68.15M | $85.49M | $2.28M | $1.04M | $653.40K | $1.28M | $3.54M |
| Cash and equivalents | $18.60M | $15.17M | $50.18M | $68.04M | $85.40M | $2.20M | $894.86K | $515.25K | $1.06M | $3.46M |
| Total liabilities | $11.77M | $3.28M | $20.39M | $586.58K | $704.37K | $724.78K | $1.08M | $742.85K | $644.17K | $580.25K |
| Short-term debt | N/A | N/A | N/A | N/A | N/A | $50.80K | $28.92K | $0 | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | $46.28K | $0 | N/A | N/A |
| Shareholder equity | $33.29M | $51.89M | $27.65M | $72.69M | $89.92M | $6.68M | $5.09M | $5.04M | $5.77M | $8.09M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $36.71M | $46.75M | $55.87M | $55.98M | $45.11M | $55.17M | $43.83M | $55.10M | $70.19M | $59.90M | $71.36M | $78.88M |
| Total liabilities | $6.90M | $11.77M | $16.47M | $19.42M | $1.52M | $3.28M | $3.58M | $11.65M | $17.15M | $20.39M | $22.47M | $20.81M |
| Cash and equivalents | $17.74M | $18.60M | $20.17M | $15.41M | $13.18M | $15.17M | $16.38M | $20.84M | $32.64M | $50.18M | $61.21M | $73.43M |
| Shareholder equity | $27.51M | $33.29M | $38.11M | $35.24M | $43.59M | $51.89M | $40.25M | $43.45M | $47.71M | $39.51M | $31.37M | $36.77M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Apr 2026.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.15M | -$2.98M | -$2.15M | -$3.79M | -$4.12M | -$3.33M | -$2.34M | -$2.88M | -$5.08M | -$3.34M |
| Capital expenditures | N/A | $4 | $3 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | N/A | -$2.98M | -$2.15M | -$3.79M | -$4.12M | -$3.33M | -$2.34M | -$2.88M | -$5.08M | -$3.34M |
| Dividends paid | N/A | $1.13M | $22.46M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share repurchases | $401.63K | $2.54M | $28.20M | $13.56M | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $2.00M | -$7.00M | -$5.00M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $6.58M | -$25.03M | -$10.71M | -$13.56M | $87.31M | $4.64M | $2.73M | $2.34M | $2.68M | $4.88M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$780.89K | -$1.39M | -$786.85K | -$979.52K | -$1.99M | -$1.04M | -$509.89K | -$1.05M | -$373.30K | -$332.96K | -$177.10K | -$1.98M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $3 | $5 | $3 | $0 | $4 | $4 |
| Free cash flow | N/A | N/A | -$786.85K | -$979.52K | -$1.99M | -$1.04M | -$509.90K | -$1.05M | -$373.30K | -$332.96K | -$177.11K | -$1.98M |
Frequently Asked Questions About PMCB
What is PharmaCyte Biotech's annual revenue?
PharmaCyte Biotech reported revenue of $0 for the fiscal year ended Apr 30, 2026.
Is PharmaCyte Biotech profitable?
No. PharmaCyte Biotech reported net income of -$19.42M for the fiscal year ended Apr 30, 2026.
How much debt does PharmaCyte Biotech have?
The balance sheet dated Apr 30, 2026 reported cash and equivalents of $18.60M.
PMCB pages: Overview, Earnings, Financials, Competitors